RECOVERS - Realigning Emotion and COgnition Via prEcision Regulation networkS

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorMedical University of South Carolina

About this trial

In this research study, investigators examine how brain activity changes during tests of emotional processing, attention, and memory using multimodal neuroimaging methods including electroencephalography (EEG), functional magnetic resonance imaging (fMRI), and functional near-infrared spectroscopy (fNIRS). Transcranial magnetic stimulation (TMS) is used to probe and modulate brain networks related to cognitive flexibility and emotion regulation.

The study includes multiple related sub-studies involving healthy participants and participants with depression. Some study components focus on mechanistic modeling using non-therapeutic neurostimulation in healthy participants, while other components include interventional approaches such as individualized EEG-synchronized repetitive TMS (rTMS), cognitive tasks, and brief cognitive behavioral therapy (CBT) in participants with depression. Certain study components also evaluate CBT alone without TMS to assess behavioral intervention effects.

Eligibility criteria

Qualifiers

Age 18-65 years

Medically and psychiatrically healthy with no history of psychiatric or neurological disorders

English-speaking

Capacity to provide informed consent

Disqualifiers

Any current or past psychiatric diagnosis

Neurological disorders or history of central nervous system disease

History of seizure or epilepsy or use of medications that lower seizure threshold

Significant head injury or loss of consciousness

Trial design

Treatments tested in this trial

  • Single-Pulse Transcranial Magnetic Stimulation
  • EEG-Synchronized Repetitive Transcranial Magnetic Stimulation (rTMS)
  • Cognitive Behavioral Therapy (CBT)
  • Cognitive Flexibility and Emotion Regulation Tasks
  • Non-Synchronized Repetitive Transcranial Magnetic Stimulation

Treatment groups

120 Participants
are divided into 4 treatment groups

Sponsors and collaborators

Medical University of South Carolina

Lead sponsor

Columbia University

Collaborator

University of Oklahoma

Collaborator

Defense Advanced Research Projects Agency

Collaborator

University of Wisconsin, Madison

Collaborator